Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Growth in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 8,036 shares, a growth of 816.3% from the February 12th total of 877 shares. Based on an average daily trading volume, of 92,565 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 92,565 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BRNS. HC Wainwright increased their price target on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $4.00.

Barinthus Biotherapeutics Trading Up 10.3%

Shares of BRNS opened at $0.62 on Wednesday. The firm’s fifty day simple moving average is $0.68 and its two-hundred day simple moving average is $0.92. Barinthus Biotherapeutics has a 12 month low of $0.56 and a 12 month high of $2.92. The stock has a market capitalization of $25.31 million, a P/E ratio of -0.33 and a beta of -0.63.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. boosted its holdings in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned about 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. Institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.